Physician profile
James J Lee
NPI 1326052184
$2,860.08
in general payments reported to CMS, 2019-2025
25 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $237 · 2021: $371 · 2022: $545 · 2023: $468 · 2024: $623 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.23 |
| Education | $143.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $585.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $498.72 | 2020-2025 | Dupixent |
| Medtronic, INC. | $291.64 | 2023-2024 | Propel |
| Kaleo, INC. | $271.55 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $215.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $169.10 | 2019-2024 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $143.95 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $140.58 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.74 | 2021-2022 | |
| Greer Laboratories, INC. | $43.76 | 2020-2025 | Oralair |
| Genentech USA, INC. | $42.44 | 2024-2025 | Xolair |
| Optinose US, INC. | $39.26 | 2021 | |
| Alk-Abello, INC | $38.40 | 2021-2023 | Grastek, Ragwitek, Odactra |
| Astrazeneca Pharmaceuticals LP | $36.29 | 2020-2022 | |
| Incyte Corporation | $35.96 | 2022-2023 | Opzelura |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.20 | 2022 | |
| Olympus America INC. | $25.05 | 2024 | |
| Aimmune Therapeutics, INC. | $21.00 | 2022 | |
| Lilly USA, LLC | $19.78 | 2025 | Ebglyss, Taltz |
| Mylan Specialty L.P. | $19.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.28 | 2022 | |
| Merck Sharp & Dohme LLC | $16.70 | 2023 | |
| Hikma Pharmaceuticals USA | $13.98 | 2023 | Ryaltris |
| Aytu Biopharma, INC. | $11.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.